Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. The company is headquartered in Stockholm, Stockholm and currently employs 1,937 full-time employees. The company went IPO on 2006-09-15. The firm develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The firm has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.
Follow-Up Questions
Quelle est la performance du prix de l'action BIOVF ?
Le prix actuel de BIOVF est de $30.04, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Swedish Orphan Biovitrum AB (publ) ?
Swedish Orphan Biovitrum AB (publ) appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Swedish Orphan Biovitrum AB (publ) ?
La capitalisation boursière actuelle de Swedish Orphan Biovitrum AB (publ) est de $10.7B
Est-ce que Swedish Orphan Biovitrum AB (publ) est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 17 analystes ont établi des notations d'analystes pour Swedish Orphan Biovitrum AB (publ), y compris 5 achat fort, 9 achat, 4 maintien, 1 vente et 5 vente forte
